cytochrome P450, family 2, subfamily s, polypeptide 1
RGD ID:
1306078
Description:
Predicted to have several functions, including heme binding activity; monooxygenase activity; and thromboxane-A synthase activity. Predicted to be involved in several processes, including exogenous drug catabolic process; monocarboxylic acid metabolic process; and xenobiotic metabolic process. Localizes to intracellular membrane-bounded organelle. Orthologous to human CYP2S1 (cytochrome P450 family 2 subfamily S member 1); PARTICIPATES IN phase I biotransformation pathway via cytochrome P450; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 3-methylcholanthrene; bisphenol A.
[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Aflatoxin B1, [CYP2S1 protein co-treated with Hydrogen Peroxide] results in increased oxidation of Aflatoxin B1
[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Tretinoin, [CYP2S1 protein co-treated with Hydrogen Peroxide] results in increased oxidation of Tretinoin
[[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene] which results in increased abundance of benzo(a)pyrene-1 more ...
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP2S1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP2S1 mRNA
[CYP2S1 protein results in increased reduction of Hydroxylamine] which results in increased chemical synthesis of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP2S1 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
